BridgeBio Pharma (BBIO) has drawn investor attention after recent share price moves, with the stock up about 23% over the past month and roughly 6% over the past 3 months.
See our latest analysis for BridgeBio Pharma.
Beyond the recent monthly move, BridgeBio Pharma’s 1-year total shareholder return of about 75% and 3-year total shareholder return above 100% point to strong momentum, even as the 7-day share price return has slipped 5.25%.
If BridgeBio Pharma has sharpened your focus on high-growth healthcare opportunities, it may be worth scanning other potential AI-driven treatments through our healthcare-focused stock screener, starting with 39 healthcare AI stocks.
BridgeBio Pharma’s pipeline and recent share price jump have investors focused on the business, but the harder question is whether that optimism already sits in the current US$81.38 price or leaves room for upside.
Most Popular Narrative: 20.8% Undervalued
BridgeBio Pharma’s most followed valuation narrative pegs fair value at about $102.71 per share, well above the recent $81.38 close. This puts a spotlight on the assumptions behind that gap.
The company's late-stage pipeline, with three Phase III readouts imminent across high unmet need rare disease indications, positions BridgeBio to leverage advancements in biotechnology for potential first-to-market and best-in-class therapies, creating the opportunity for multiple revenue inflection points and margin improvement as the portfolio diversifies.
Curious what supports a higher fair value for BridgeBio Pharma? The core of this narrative leans on steep revenue expansion, rising margins, and a richer profit multiple anchored to those projections. Want to see which specific growth and earnings paths are baked into that model and how a single discount rate ties it all together?
Result: Fair Value of $102.71 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, BridgeBio Pharma’s story can shift quickly if Attruby underperforms expectations or if key Phase 3 programs disappoint, which would challenge the current fair value narrative.
Find out about the key risks to this BridgeBio Pharma narrative.
Another View: What Multiples Say About BridgeBio Pharma
There is a clear tension between the fair value narrative for BridgeBio Pharma and what its current trading multiple signals. The stock trades on a P/S of 27.5x, compared with 11.3x for the US Biotechs industry, 17.4x for close peers, and a fair ratio of 23.1x that the market could move toward. That premium suggests investors are already paying up for future growth, which raises the question of how much execution risk you are comfortable with at today’s price.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment on BridgeBio Pharma clearly mixed, with both risks and rewards in play, it may be helpful to move quickly and test the numbers yourself, then weigh up the 2 key rewards and 1 important warning sign.
Looking for more BridgeBio Pharma style investment ideas?
If BridgeBio Pharma has sharpened your interest, do not stop here; use the Simply Wall Street Screener to quickly spot other stocks that fit your game plan.
- Target reliable cash generators with stronger defensiveness by reviewing the solid balance sheet and fundamentals stocks screener (47 results), which is tailored to companies that pair stability with fundamental strength.
- Pursue mispriced opportunities by scanning the 47 high quality undervalued stocks, which highlights companies combining quality metrics with prices that may sit below their assessed worth.
- Hunt for potential future standouts before they are widely followed by using the screener containing 20 high quality undiscovered gems, which is built to surface lesser known stocks with solid underpinnings.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com